Clinical trials: Bortezomib
Multiple Myeloma
Treatment of Relapsed/Refractory Multiple Myeloma (rrMM) With Pomalidomide in Clinical Practice
There is a high unmet medical need for an anti-myeloma therapy for RRMM patients previously treated with Lenalidomide and Bortezomib, due to poor prognosis.
- Trial name
- NCT02555839
- Testing
- Pomalidomide, Dexamethasone, Bortezomib
- Where
- 13 sites in Austria
- Volunteers
- 127 people
- Sponsor
- Celgene
Multiple Myeloma
China Subpopulation: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
This study is designed to evaluate safety and efficacy of belantamab mafodotin in combination with bortezomib/dexamethasone versus daratumumab in combination with bortezomib/dexamethasone in the Chinese participants with…
- Trial name
- DREAMM 7 (NCT06868654)
- Testing
- Belantamab mafodotin, Daratumumab, Bortezomib
- Where
- 11 sites in China
- Volunteers
- 72 people
- Sponsor
- GlaxoSmithKline
Multiple Myeloma
Study of Mapatumumab in Combination With Bortezomib (Velcade) and Bortezomib Alone in Subjects With Relapsed or Refractory Multiple Myeloma
The purpose of this study is to evaluate the efficacy (disease response) and safety of mapatumumab in combination with bortezomib and bortezomib alone in subjects with relapsed or refractory multiple myeloma (MM).
- Trial name
- NCT00315757
- Testing
- Mapatumumab, Bortezomib
- Where
- 20 sites in United States, Australia and 2 more
- Volunteers
- 105 people
- Sponsor
- Human Genome Sciences Inc.
Relapsed or Refractory Multiple Myeloma
Mitoxantrone Hydrochloride Liposome Injection, Bortezomib and Dexamethasone in the Treatment of R/R MM
The purpose of this study is to evaluate the safety and efficacy of mitoxantrone hydrochloride liposome injection in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma.
- Trial name
- NCT05052970
- Testing
- Mitoxantrone Hydrochloride Liposome injection, Bortezomib for Injection, Dexamethasone Acetate Tablets
- Where
- China
- Volunteers
- 60 people
- Sponsor
- CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
Relapsed or Refractory Multiple Myeloma (RRMM)
A Multicenter, Randomized, Open-label, Parallel-group, Controlled, Superiority Phase III Clinical Study Comparing the Efficacy and Safety of F182112 Versus Standard of Care in Patients With Relapsed or Refractory Multiple Myeloma
A Multicenter, Randomized, Open-label, Parallel-group, Controlled, Superiority Phase III Clinical Study Comparing F182112 with Standard of Care in Patients with Relapsed or Refractory Multiple Myeloma
- Trial name
- NCT07579234
- Testing
- F182112 single-agent, Pomalidomide + Bortezomib + Dexamethasone (PVd) or Selinexor + Bortezomib + Dexamethasone (SVd)
- Where
- China
- Volunteers
- 261 people
- Sponsor
- Shandong New Time Pharmaceutical Co., LTD